STOCK TITAN

Intelligent Bio Solutions (NASDAQ: INBS) reports 3,018,188 shares

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Intelligent Bio Solutions Inc. reported that its total outstanding common stock was 3,018,188 shares as of the close of business on July 31, 2026. This updated share count reflects sales under an At The Market Offering Agreement, exercises of previously issued warrants, and issuances of restricted shares under an investor relations and corporate development advisory agreement.

Positive

  • None.

Negative

  • None.

Filing Explained

The reported common-share count increased from 1,216,142 on January 2, 2026 to 3,018,188 on July 31, 2026; absent offsetting changes, that larger base reduces each existing holder’s percentage ownership.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Shares outstanding 3,018,188 shares Total common shares outstanding as of close of business on July 31, 2026
Par value per share $0.01 per share Par value of Intelligent Bio Solutions Inc. common stock
Commission File Number 001-39825 SEC registration file number for Intelligent Bio Solutions Inc.
IRS Employer Identification Number 82-1512711 Federal tax identification number of Intelligent Bio Solutions Inc.
At The Market Offering Agreement financial
"pursuant to the previously disclosed At The Market Offering Agreement"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
warrants to purchase common stock financial
"the exercise of previously disclosed outstanding warrants to purchase common stock"
restricted common stock financial
"the issuance of shares of restricted common stock pursuant to the agreement"
Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.
Emerging growth company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Intelligent Bio Solutions Inc. (INBS) report about its share count?

Intelligent Bio Solutions Inc. reported that it had 3,018,188 shares of common stock outstanding as of the close of business on July 31, 2026. The updated figure consolidates recent stock sales, warrant exercises and restricted stock issuances.

As of what date does INBS’s 3,018,188 outstanding shares figure apply?

The 3,018,188 outstanding common shares for Intelligent Bio Solutions Inc. apply as of the close of business on July 31, 2026. The date anchors the share count for investors tracking ownership changes over time.

What contributed to the updated outstanding share count for INBS?

The updated 3,018,188-share count reflects three factors: sales of common stock under an At The Market Offering Agreement, exercises of outstanding warrants, and issuances of restricted common stock under an investor relations and corporate development advisory agreement.

Which agreements affected INBS’s outstanding common stock total?

The share count was affected by an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. and an Investor Relations and Corporate Development Advisory Agreement with ClearThink Capital Partners LLC, along with exercises of previously disclosed warrants.

What type of securities make up INBS’s 3,018,188 outstanding shares?

The 3,018,188 outstanding shares reported by Intelligent Bio Solutions Inc. consist of its common stock with a par value of $0.01 per share. These shares trade on The Nasdaq Stock Market LLC under the symbol INBS.
false 0001725430 0001725430 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): July 31, 2026

 

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39825   82-1512711

(State of

Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

135 West 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (646) 790-5756

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   INBS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As a result of (a) the sale of shares of common stock by Intelligent Bio Solutions Inc. (the “Company”) pursuant to the previously disclosed At The Market Offering Agreement, dated September 18, 2024, between the Company and Ladenburg Thalmann & Co. Inc.; (b) the exercise of previously disclosed outstanding warrants to purchase common stock; and (c) the issuance of shares of restricted common stock pursuant to the previously disclosed Investor Relations and Corporate Development Advisory Agreement, dated February 29, 2024, between the Company and ClearThink Capital Partners LLC, the total number of outstanding shares of the Company’s common stock as of the close of business on July 31, 2026, is 3,018,188 shares.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 3, 2026

 

  INTELLIGENT BIO SOLUTIONS INC.
     
  By: /s/ Spiro Sakiris
  Name:  Spiro Sakiris
  Title: Chief Financial Officer

 

 

 

Filing Exhibits & Attachments

3 documents